Literatura académica sobre el tema "Maytansinoids"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Maytansinoids".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Maytansinoids"
Giles, Francis, Rodica Morariu-Zamfir, John Lambert, Srdan Verstovsek, Deborah Thomas, Farhad Ravandi y Dan Deangelo. "Phase I Study of AVE9633, an AntiCD33-Maytansinoid Immunoconjugate, Administered as an Intravenous Infusion in Patients with Refractory/Relapsed CD33-Positive Acute Myeloid Leukemia (AML)." Blood 108, n.º 11 (16 de noviembre de 2006): 4548. http://dx.doi.org/10.1182/blood.v108.11.4548.4548.
Texto completoPlattner, Ronald D. y Richard G. Powell. "Tandem Mass Spectrometry of Maytansinoids". Journal of Natural Products 49, n.º 3 (mayo de 1986): 475–82. http://dx.doi.org/10.1021/np50045a016.
Texto completoLarson, Gretchen M., Brian T. Schaneberg y Albert T. Sneden. "Two New Maytansinoids fromMaytenus buchananii". Journal of Natural Products 62, n.º 2 (febrero de 1999): 361–63. http://dx.doi.org/10.1021/np9803732.
Texto completoLo, Chen-Fu, Tai-Yu Chiu, Yu-Tzu Liu, Li-Rung Huang, Teng-Kuang Yeh, Kuan-Hsun Huang, Kuan-Liang Liu et al. "Synthesis and Evaluation of Small Molecule Drug Conjugates Harnessing Thioester-Linked Maytansinoids". Pharmaceutics 14, n.º 7 (21 de junio de 2022): 1316. http://dx.doi.org/10.3390/pharmaceutics14071316.
Texto completoNittoli, Thomas, Frank Delfino, Marcus Kelly, Serena Carosso, Thomas Markotan, Arthur Kunz, Zhaoyuan Chen et al. "Antibody drug conjugates of cleavable amino-benzoyl-maytansinoids". Bioorganic & Medicinal Chemistry 28, n.º 23 (diciembre de 2020): 115785. http://dx.doi.org/10.1016/j.bmc.2020.115785.
Texto completoSuchocki, John A. y Albert T. Sneden. "New maytansinoids: reduction products of the C(9)-carbinolamide". Journal of Organic Chemistry 53, n.º 17 (agosto de 1988): 4116–18. http://dx.doi.org/10.1021/jo00252a047.
Texto completoLadino, Cynthia A., Ravi V. J. Chari, Lizabeth A. Bourret, Nancy L. Kedersha y Victor S. Goldmacher. "Folate-maytansinoids: Target-selective drugs of low molecular weight". International Journal of Cancer 73, n.º 6 (10 de diciembre de 1997): 859–64. http://dx.doi.org/10.1002/(sici)1097-0215(19971210)73:6<859::aid-ijc16>3.0.co;2-#.
Texto completoPerrino, Elena, Martina Steiner, Nikolaus Krall, Gonçalo J. L. Bernardes, Francesca Pretto, Giulio Casi y Dario Neri. "Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids". Cancer Research 74, n.º 9 (11 de febrero de 2014): 2569–78. http://dx.doi.org/10.1158/0008-5472.can-13-2990.
Texto completoNittoli, Thomas, Marcus P. Kelly, Frank Delfino, John Rudge, Arthur Kunz, Thomas Markotan, Jan Spink et al. "Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids". Bioorganic & Medicinal Chemistry 26, n.º 9 (mayo de 2018): 2271–79. http://dx.doi.org/10.1016/j.bmc.2018.02.025.
Texto completoLiu, C., B. M. Tadayoni, L. A. Bourret, K. M. Mattocks, S. M. Derr, W. C. Widdison, N. L. Kedersha et al. "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids." Proceedings of the National Academy of Sciences 93, n.º 16 (6 de agosto de 1996): 8618–23. http://dx.doi.org/10.1073/pnas.93.16.8618.
Texto completoTesis sobre el tema "Maytansinoids"
Hodgson, D. M. "Synthetic studies towards the maytansinoids". Thesis, University of Southampton, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.330146.
Texto completoPrinciotto, S. "Synthesis of intermediates for the preparation of Active Pharmaceutical Ingredients (APIs)". Doctoral thesis, Università di Siena, 2020. http://hdl.handle.net/11365/1095607.
Texto completoInositols are a class of 9 compounds characterized by the presence of the cyclohexan-hex-ol moiety, with different stereochemical configuration of the carbons present upon the structure. In particular, myo-inositol is widely present in nature (plants and mammals), mostly in form of phytate (as phosphorus reservoir within the plants) and as important components of cellular membrane (phosphatidyl inositol phosphates) or second messengers of intracellular signaling cascades (inositol triphosphate, IP3). Due to its very important role within different physiological conditions, in the second section of this thesis the performed reactivity studies about myo-inositol were described. In particular, the different regio- and stereoselectivities in presence of different reaction conditions were reported. Different protection protocols for the myo-inositol orthoformate were established and the results were rationalized and applied for the total synthesis of a natural origin compound, with particular attention to the desymmetrization process, necessary for the obtainment of optically pure derivatives.
Meurer, Kristina. "Untersuchungen zum Vorkommen von Maytansinoiden in Höheren Pflanzen : ein Beitrag zur Suche nach einem maytansinproduzierenden Mikroorganismus /". [S.l. : s.n.], 2002. http://www.gbv.de/dms/bs/toc/356980243.pdf.
Texto completoBrünjes, Marco. "Studien zur chemoenzymatischen Synthese und Biosynthese von Maytansinoid-Analoga". [S.l.] : [s.n.], 2006. http://deposit.ddb.de/cgi-bin/dokserv?idn=98052542X.
Texto completoFrenzel, Thomas. "Studien zur chemoenzymatischen Synthese von Maytansinoid-Analoga Synthese von seco-Proansamitocin /". [S.l.] : [s.n.], 2005. http://deposit.ddb.de/cgi-bin/dokserv?idn=977228118.
Texto completoBrünjes, Marco [Verfasser]. "Studien zur chemoenzymatischen Synthese und Biosynthese von Maytansinoid-Analoga / von Marco Brünjes". 2006. http://d-nb.info/98052542X/34.
Texto completoMERLINO, GIUSEPPE. "Characterization of MEN1309/OBT076, a new antibody conjugated to the DM4 maytansinoide toxin". Doctoral thesis, 2020. http://hdl.handle.net/11573/1341225.
Texto completoFrenzel, Thomas [Verfasser]. "Studien zur chemoenzymatischen Synthese von Maytansinoid-Analoga : Synthese von seco-Proansamitocin / von Thomas Frenzel". 2005. http://d-nb.info/977228118/34.
Texto completoCapítulos de libros sobre el tema "Maytansinoids"
Erickson, Hans. "Antibody-Maytansinoid Conjugates: From the Bench to the Clinic". En Drug Delivery in Oncology, 375–94. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2011. http://dx.doi.org/10.1002/9783527634057.ch13.
Texto completoWiddison, Wayne C. "CHAPTER 5. Maytansinoid Payloads for Antibody–Drug Conjugates (ADCs)". En Cytotoxic Payloads for Antibody–Drug Conjugates, 100–116. Cambridge: Royal Society of Chemistry, 2019. http://dx.doi.org/10.1039/9781788012898-00100.
Texto completoLambert, John M., Veronique Blanc, Nathalie Le Bail y Anne Bousseau. "Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies". En Antibody-Drug Conjugates and Immunotoxins, 149–60. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-5456-4_9.
Texto completo"Maytansinoids". En Encyclopedia of Genetics, Genomics, Proteomics and Informatics, 1166. Dordrecht: Springer Netherlands, 2008. http://dx.doi.org/10.1007/978-1-4020-6754-9_9986.
Texto completo"Ansamitocins (Maytansinoids)". En Anticancer Agents from Natural Products, 423–44. CRC Press, 2011. http://dx.doi.org/10.1201/b11185-21.
Texto completo"Ansamitocins (Maytansinoids)". En Anticancer Agents from Natural Products, 337–54. CRC Press, 2005. http://dx.doi.org/10.1201/9781420039658-21.
Texto completoActas de conferencias sobre el tema "Maytansinoids"
Sala, Gianluca, Emily Capone, Enza Piccolo, Sara Ponziani, Roberta Gentile, Rodolfo Ippoliti, Francesco Giansanti y Stefano Iacobelli. "Abstract 748: Non-internalizing site-specific antibody-drug conjugates based on maytansinoids display curative properties". En Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-748.
Texto completoNollmann, Friederike I., Patricia Perez Galan, Javier Garcia Fernandez, Heidi K. Walter, Johannes P. Magnusson, Federico Medda, Felix Kratz et al. "Abstract 1657: Structure-activity relationship studies and biological evaluation of novel maytansinoids, a class of highly selective tubulin inhibitors". En Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1657.
Texto completoNollmann, Friederike I., Patricia Perez Galan, Javier Garcia Fernandez, Heidi K. Walter, Johannes P. Magnusson, Federico Medda, Felix Kratz et al. "Abstract 2661: Novel albumin-binding maytansinoids inducing long-term partial and complete tumor regressions in several human cancer xenograft models in nude mice". En Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2661.
Texto completoWhiteman, Kathleen R., Holly A. Johnson, Xiuxia Sun, Robert Mastico, Susan Emrich, Lauren Clancy, Hans Erickson y Jan Pinkas. "Abstract 4628: Anti-tumor activity and pharmacokinetics of the anti-FOLR1-maytansinoid conjugate IMGN853 is maintained over a wide range of maytansinoid-to-antibody ratios". En Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4628.
Texto completoWiddison, Wayne C., Sharon Wilhelm, Karen Veale, Yelena Kovtun, Hans Erickson, Charlene Audette, Barbara Leeca, Gregory Jones y Ravi Chari. "Abstract 2668: Detoxification of metabolites from antibody-maytansinoid conjugates by human liver microsomes". En Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2668.
Texto completoSun, Xiuxia, Jose F. Ponte, Nicholas C. Yoder, Jennifer Coccia, Leanne Lanieri, Rassol Laleau, Qifeng Qiu et al. "Abstract 4531: Effects of drug load on therapeutic index for antibody-maytansinoid conjugates". En Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4531.
Texto completoKellogg, Brenda, Charlene Audette, Hans Erickson, Michelle Mayo, Michael Okamoto, Jan Pinkas, Xiuxia Sun et al. "Abstract 4404: Comparativein vivopharmacokinetic properties of antibody-maytansinoid conjugates with alternative non-cleavable linkers". En Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-4404.
Texto completoSingh, Rajeeva, Nathan Fishkin, Yelena Kovtun, Gregory Jones, Jose Ponte, Hans Erickson, Erica Hong et al. "Abstract C164: New tri-glycyl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs)." En Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-c164.
Texto completoAb, Olga, Laura M. Bartle, Lingyun Rui, Jennifer Coccia, Holly A. Johnson, Kathleen R. Whiteman, Brenda Kellogg, Lauren Clancy, Xiuxia Sun y Victor S. Goldmacher. "Abstract 4576: IMGN853, an anti-Folate Receptor I antibody-maytansinoid conjugate for targeted cancer therapy". En Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4576.
Texto completoWiddison, Wayne C., Joe Ponte, Jennifer Coccia, Yulius Setiady, Ling Dong, Anja Skaletskaya, Nathan Fishkin et al. "Abstract 1618: New peptide-linked anilino-maytansinoid antibody-drug conjugates (ADCs) for the treatment of cancer". En Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1618.
Texto completo